← Leaderboards
Wilson Wong
Boston University (Charles River Campus)
$8,399,937
Attributed
$12,957,207
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,957,207 · 8
By mechanism
R01$7,605,351 · 5
U01$2,539,139 · 1
DP2$2,455,500 · 1
R56$357,217 · 1
Top collaborators
- Yolonda L Colson6 shared
- Mark W Grinstaff6 shared
- Michael Birnbaum4 shared
- Curtis Lisante Cetrulo4 shared
- Sally Choate Kent4 shared
- Hans Peter Dooms1 shared
- Andrew Emili1 shared
Most similar at Boston University (Charles River Campus)
Same institution · by research overlap
- Yolonda L Colson$10,834,927
- Mark W Grinstaff$24,362,733
- Eric Bressler$209,456
- Sarah C Adams$83,410
- Aria Pearlman Morales$108,512
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignCellsEngineeringSuccessPublishingSiteSignal TransductionSpecificityPreventChimeric Antigen Receptor T CellsLogicIn VivoMalignant NeoplasmsTumorSmall MoleculeAntigensPublic HealthGenesCar T Cell TherapyGeneticTechnologyExtracellularGene ExpressionMammalian Cell
Grant awards (24)
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$764,333
R01 · FY2025 · DK · contact PI
Modified saRNA Encoded BiTEs for Lung Cancer$635,248
R01 · FY2025 · CA
Engineering recombinase circuits for cellular diagnostic devices$509,894
R01 · FY2025 · EB · contact PI
Precise tumor targeting with logic CAR circuits$323,559
U01 · FY2025 · CA · contact PI
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$769,703
R01 · FY2024 · DK · contact PI
Precise tumor targeting with logic CAR circuits$525,026
U01 · FY2024 · CA · contact PI
Engineering recombinase circuits for cellular diagnostic devices$478,544
R01 · FY2024 · EB · contact PI
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13$388,951
R01 · FY2024 · EB · contact PI
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$674,605
R01 · FY2023 · DK · contact PI
Precise tumor targeting with logic CAR circuits$553,669
U01 · FY2023 · CA · contact PI
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13$396,889
R01 · FY2023 · EB · contact PI
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands$728,516
R01 · FY2022 · DK · contact PI
Precise tumor targeting with logic CAR circuits$554,582
U01 · FY2022 · CA · contact PI
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13$396,889
R01 · FY2022 · EB · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$330,000
R01 · FY2022 · GM · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$36,223
R01 · FY2022 · GM · contact PI
Precise tumor targeting with logic CAR circuits$582,303
U01 · FY2021 · CA · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$402,445
R01 · FY2021 · GM · contact PI
Multiplexed and Logical Control of the Mammalian Transcriptome Using Cas13$396,889
R01 · FY2021 · EB · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$330,000
R01 · FY2020 · GM · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$36,222
R01 · FY2020 · GM · contact PI
Engineering a smart CAR platform for human regulatory T cells$357,217
R56 · FY2019 · EB · contact PI
Advanced recombinase-based gene expression technology in mammalian cells$330,000
R01 · FY2019 · GM · contact PI
Synthetically Reengineered T cells as the Next Generation of Smart Cancer Therapy$2,455,500
DP2 · FY2013 · CA · contact PI